drugset / Trial / NCT06663059
Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study
RandomizedParallel-groupOpen-labelTreatment
Summary
Observing the efficacy and safety of 2 cycles versus 4 cycles of Adebrelimab combined with chemotherapy as neoadjuvant treatment for patients with resectable locally advanced thoracic esophageal squamous cell carcinoma.
Timeline
- Start
- 2024-10-01
- Primary completion
- 2025-12-01
- Completion
- 2027-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Albumin-Bound Paclitaxel | Unknown | 130 mg/m2 | Intravenous |
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |